2seventy bio Statistics
Total Valuation
2seventy bio has a market cap or net worth of $259.07 million. The enterprise value is $319.17 million.
Important Dates
The last earnings date was Tuesday, March 25, 2025, after market close.
| Earnings Date | Mar 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
2seventy bio has 52.34 million shares outstanding. The number of shares has increased by 5.97% in one year.
| Current Share Class | 52.34M |
| Shares Outstanding | 52.34M |
| Shares Change (YoY) | +5.97% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | 4.35% |
| Owned by Institutions (%) | 74.47% |
| Float | 44.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.83 |
| Forward PS | 4.23 |
| PB Ratio | 1.21 |
| P/TBV Ratio | 1.26 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.43 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.67, with a Debt / Equity ratio of 1.16.
| Current Ratio | 4.67 |
| Quick Ratio | 4.55 |
| Debt / Equity | 1.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -24.56% and return on invested capital (ROIC) is -13.65%.
| Return on Equity (ROE) | -24.56% |
| Return on Assets (ROA) | -12.63% |
| Return on Invested Capital (ROIC) | -13.65% |
| Return on Capital Employed (ROCE) | -24.02% |
| Revenue Per Employee | $138,182 |
| Profits Per Employee | -$208,931 |
| Employee Count | 274 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.99% in the last 52 weeks. The beta is 1.74, so 2seventy bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.74 |
| 52-Week Price Change | -7.99% |
| 50-Day Moving Average | 3.24 |
| 200-Day Moving Average | 3.94 |
| Relative Strength Index (RSI) | 80.79 |
| Average Volume (20 Days) | 2,544,705 |
Short Selling Information
The latest short interest is 5.14 million, so 9.82% of the outstanding shares have been sold short.
| Short Interest | 5.14M |
| Short Previous Month | 5.18M |
| Short % of Shares Out | 9.82% |
| Short % of Float | 11.54% |
| Short Ratio (days to cover) | 1.45 |
Income Statement
In the last 12 months, 2seventy bio had revenue of $37.86 million and -$57.25 million in losses. Loss per share was -$1.10.
| Revenue | 37.86M |
| Gross Profit | -61.62M |
| Operating Income | -105.54M |
| Pretax Income | -156.25M |
| Net Income | -57.25M |
| EBITDA | -98.45M |
| EBIT | -105.54M |
| Loss Per Share | -$1.10 |
Full Income StatementBalance Sheet
The company has $174.75 million in cash and $243.72 million in debt, giving a net cash position of -$60.10 million or -$1.15 per share.
| Cash & Cash Equivalents | 174.75M |
| Total Debt | 243.72M |
| Net Cash | -60.10M |
| Net Cash Per Share | -$1.15 |
| Equity (Book Value) | 210.81M |
| Book Value Per Share | 4.09 |
| Working Capital | 147.16M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$85.00 million and capital expenditures -$707,000, giving a free cash flow of -$85.71 million.
| Operating Cash Flow | -85.00M |
| Capital Expenditures | -707,000 |
| Free Cash Flow | -85.71M |
| FCF Per Share | -$1.64 |
Full Cash Flow StatementMargins
Gross margin is -162.74%, with operating and profit margins of -278.75% and -151.20%.
| Gross Margin | -162.74% |
| Operating Margin | -278.75% |
| Pretax Margin | -151.20% |
| Profit Margin | -151.20% |
| EBITDA Margin | -260.01% |
| EBIT Margin | -278.75% |
| FCF Margin | n/a |
Dividends & Yields
2seventy bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.97% |
| Shareholder Yield | -5.97% |
| Earnings Yield | -22.10% |
| FCF Yield | -33.08% |
Analyst Forecast
The average price target for 2seventy bio is $7.60, which is 53.54% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.60 |
| Price Target Difference | 53.54% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 18.76% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
2seventy bio has an Altman Z-Score of -1.43 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.43 |
| Piotroski F-Score | 1 |